We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Roche Wins EU Approval of Gazyvaro for Chronic Lymphocytic Leukemia
Roche Wins EU Approval of Gazyvaro for Chronic Lymphocytic Leukemia
European regulators have approved Roche’s Gazyvaro in combination with chlorambucil as a first-line treatment for chronic lymphocytic leukemia (CLL) patients who are unable to tolerate more intensive therapies.